GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

GSK chief executive Andrew Witty told investors ... replace Advair/Seretide missed consensus estimates, with Breo (fluticasone furoate and vilanterol) bringing in £11 million and Anoro ...

Fluticasone furoate, vilanterol 50/25mcg, 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity.

In the INS class, fluticasone propionate (Flonase; GlaxoSmithKline (GSK)) reached ... As an example, both market share and sales of mometasone furoate (Nasonex; Schering–Plough) increased ...